Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.53 USD
Change Today +0.02 / 0.12%
Volume 6.5M
BSX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 Boston Scientific Way

Marlborough, MA 01752

United States

Phone: 508-683-4000

Fax:

ral stent technology includes its EPIC self-expanding nitinol stent system, its Carotid WALLSTENT stent system, and its Innova self-expanding stent system. In addition, the company markets its 0.035 inch Rubicon Support Catheter and its Direxion torqueable microcatheter in both the U.S. and Europe. The company has also launched in Europe a catheter-based renal denervation system for the treatment of uncontrolled hypertension, which it obtained through its acquisition of Vessix Vascular, Inc. In addition, the company is conducting a study designed to evaluate the safety and performance of the self-expanding Innova drug-eluting stent system designed to treat Superficial Femoral Artery lesions. During 2014, the company completed the acquisition of the Interventional Division of Bayer AG (Bayer). The addition of Bayer's commercial organization and innovative technologies supports the company’s strategy to provide a portfolio of major solutions to treat peripheral vascular disease. The transaction includes the major AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins; and the JetStream Atherectomy System, used in a therapy to remove plaque and thrombi from diseased arteries. The company also sells products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The company continues to market its line of Interventional Oncology product solutions, including the newly launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. Rhythm Management Cardiac Rhythm Management The company develops, manufactures, and markets various implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including the commercially available subcutaneous implantable cardiac defibrillator - the S-ICD System, and implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure; and implantable pacemaker systems used to manage slow or irregular heart rhythms (bradycardia), including implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure. In addition, majority of the company’s implantable device systems include its remote LATITUDE Patient Management System, which enables physicians to monitor device performance remotely, allowing for frequent monitoring to guide treatment decisions. The company markets its INGENIO family of pacemaker systems in the U.S., Europe, and Japan. Its INGENIO and ADVANTIO pacemakers are approved in Europe and Japan for use in patients in need of a magnetic resonance imaging scan. The company’s cardiac resynchronization therapy pacemaker product offerings include its INVIVE system, which is built on the same platform as its high voltage cardiac resynchronization therapy defibrillator, is enabled for remote patient monitoring, and includes features that promote ease of use. The company owns Cameron Health, Inc. (Cameron). Cameron developed the commercially available subcutaneous implantable cardiac defibrillator - the S-ICD System, which is a differentiated technology. The S-ICD system has Conformité Européenne (CE) Mark and the U.S. Food and Drug Administration (FDA) approval. With this technology, the company offers its physician customers a new option to treat their patients who are at risk for sudden cardiac arrest without touching the heart or invading the vasculature. In 2013, the company received CE Mark approval and performed the first implants of its X4 line of quadripolar CRT-D systems, including AUTOGEN X4, DYNAGEN X4, and INOGEN X4 cardiac resynchronization therapy defibrillators, a suit

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $16.53 USD +0.02

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,693 JPY -7.50
Becton Dickinson and Co $136.53 USD -0.19
Olympus Corp ¥4,165 JPY +15.00
St Jude Medical Inc $70.38 USD -0.68
Zimmer Biomet Holdings Inc $102.09 USD +0.46
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.4x
Price/Cash Flow 75.5x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.